One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

NCT00627796 ·Status: COMPLETED ·Phase: PHASE4

Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

NCT02396966 ·Status: COMPLETED

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

NCT00701363 ·Status: COMPLETED ·Phase: PHASE4

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

NCT00444873 ·Status: COMPLETED ·Phase: PHASE3

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

NCT00145405 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly

NCT00499993 ·Status: COMPLETED ·Phase: PHASE3

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

NCT02698384 ·Status: TERMINATED

Somatuline Predictive Factors in Acromegaly and NET

NCT01840449 ·Status: COMPLETED

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708 ·Status: COMPLETED ·Phase: PHASE3

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499 ·Status: COMPLETED ·Phase: PHASE3

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

NCT04003519 ·Status: WITHDRAWN

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

NCT00993356 ·Status: UNKNOWN ·Phase: PHASE2

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

NCT06607666 ·Status: COMPLETED

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

NCT01861717 ·Status: TERMINATED ·Phase: PHASE4

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

NCT00216398 ·Status: COMPLETED ·Phase: PHASE4

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

NCT00242541 ·Status: TERMINATED ·Phase: PHASE4

Non Interventional Post Marketing Programme in Acromegaly

NCT00747500 ·Status: COMPLETED

Acromegaly Combination Treatment Study

NCT01538966 ·Status: TERMINATED ·Phase: NA

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

NCT00225979 ·Status: COMPLETED ·Phase: PHASE3

Late Effects of Radiosurgery on Acromegaly Study

NCT02296216 ·Status: COMPLETED ·Phase: NA

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

NCT05431803 ·Status: COMPLETED

Octreotide Efficacy and Safety in First-line Acromegalic Patients

NCT00171886 ·Status: COMPLETED ·Phase: PHASE4

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071 ·Status: COMPLETED ·Phase: PHASE4